

# Brunei Darussalam

## Tuberculosis profile

Population 2018

<1 million

Estimates of TB burden <sup>o</sup> , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	0.29 (0.25–0.33)	68 (58–78)
HIV-positive TB incidence	<0.01 (0–<0.01)	0.8 (0.1–2.2)
MDR/RR-TB incidence <sup>oo</sup>	0 (0–0)	0 (0–0)
HIV-negative TB mortality	0.016 (0.015–0.016)	3.6 (3.6–3.7)
HIV-positive TB mortality	0 (0–<0.01)	0.12 (0.01–0.35)

### Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases	0% (0–1.9)
Previously treated cases	0% (0–60)

### TB case notifications, 2018

Total new and relapse	252
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	100%
- % pulmonary	81%
- % bacteriologically confirmed <sup>ooo</sup>	98%
- % children aged 0–14 years	2%
- % women	41%
- % men	57%
Total cases notified	252

### Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2018	6% (5–7)

### TB/HIV care in new and relapse TB patients, 2018

	Number	(%)
Patients with known HIV status who are HIV-positive	3	1%
- on antiretroviral therapy	3	100%

### Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance <sup>ooo</sup>	
- New cases	100%
- Previously treated cases	100%
Laboratory-confirmed cases*	MDR/RR-TB: 0, XDR-TB: 0
Patients started on treatment**	MDR/RR-TB: 0, XDR-TB: 0
MDR/RR-TB cases tested for resistance to second-line drugs	0

### Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2017	75%	238
Previously treated cases, excluding relapse, registered in 2017		0
HIV-positive TB cases registered in 2017	50%	2
MDR/RR-TB cases started on second-line treatment in 2016		0
XDR-TB cases started on second-line treatment in 2016		0

### TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment	0%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	0% (0–0)

### TB financing, 2019

National TB budget (US\$ millions)

<sup>o</sup> Ranges represent uncertainty intervals


<sup>oo</sup> MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

<sup>ooo</sup> Calculated for pulmonary cases only

\* Includes cases with unknown previous TB treatment history


\*\* Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




Legend:  
■ Total TB incidence  
■ New and relapse TB cases notified  
■ HIV-positive TB incidence

(Rate per 100 000 population per year)




Legend:  
■ HIV-negative TB mortality

### Notified cases by age group and sex, 2018




Legend:  
■ Females ■ Males  Incidence

Treatment success rate (%)



Legend:  
■ New and relapse  
■ Retreatment, excluding relapse  
■ HIV-positive ■ MDR/RR-TB ■ XDR-TB

Total budget (US\$ millions)



Legend:  
■ Unfunded  
■ Funded internationally  
■ Funded domestically